Michigan Prior Authorization Request Form
For Prescription Drugs Instructions

Important: Please read all instructions below before completing FIS 2288.

Section 2212c of Public Act 218 of 1956, MCL 500.2212c, requires the use of a standard prior authorization form when a policy, certificate or contract requires prior authorization for prescription drug benefits.

A standard form, FIS 2288, is being made available by the Department of Insurance and Financial Services to simplify exchanges of information between prescribers and health insurers as part of the process of requesting prescription drug prior authorization. This form will be updated periodically and the form number and most recent revision date are displayed in the top left-hand corner.

- **This form is made available for use by prescribers to initiate a prior authorization request with the health insurer.**
- Prior authorization requests are defined as requests for pre-approval from an insurer for specified medications or quantities of medications before they are dispensed.
- "Prescriber" means the term as defined in section 17708 of the Public Health Code, 1978 PA 368, MCL
- 333.17708.
- "Prescription drug" means the term as defined in section 17708 of the Public Health Code, 1978 PA 368, MCL 333.17708.
- Pursuant to MCL 500.2212c, prescribers and insurers must comply with required timeframes pertaining to the processing of a prior authorization request. Insurers may request additional information or clarification needed to process a prior authorization request.
- The prior authorization is considered granted if the insurer fails to grant the request, deny the request, or require additional information of the prescriber within 72 hours after the date and time of submission of an expedited prior authorization request or within 15 days after the date and time of submission of a standard prior authorization request. If additional information is requested by an insurer, a prior authorization request is considered to have been granted by the insurer if the insurer fails to grant the request, deny the request, or otherwise respond to the request of the prescriber within 72 hours after the date and time of submission of the additional information for an expedited prior authorization request; or within 15 days after the date and time of submission of the additional information for standard prior authorization request.
- The prior authorization is considered void if the prescriber fails to submit the additional information within 5 days after the date and time of the original submission of a properly completed expedited prior authorization request or within 21 days after the date and time of the original submission of a properly completed standard prior authorization request.
- In order to designate a prior authorization request for expedited review, a prescriber must certify that applying the 15-day standard review period may seriously jeopardize the life and health of the patient or the patient's ability to regain maximum function.

PRESCRIBERS, PLEASE SUBMIT THIS FORM TO THE PATIENT'S HEALTH PLAN ONLY. Please do not send to the department.

Only provide the physician's direct contact number and initials if you are requesting an Expedited Review Request.

Print Reset

Michigan Prior Authorization
Request Form for Prescription Drugs

Fax: 800-424-7648

(PRESCRIBERS SUBMIT THIS FORM TO THE PATIENT'S HEALTH PLAN)

☐ **Standard Review Request**

☐ **Expedited Review Request:** *I hereby certify that a standard review period may seriously jeopardize the life or health of the patient or the patient's ability to regain maximum function.*

Physician's Direct Contact Phone Number: _____ **Initials:** _____

A) Reason for Request

☐ Initial Authorization Request ☐ Renewal Request ☐ DAW

B) Patient Demographics

Is patient hospitalized: ☐ Yes ☐ No

Patient Name: _____ DOB: _____

Patient Health Plan ID: _____ ☐ Male ☐ Female

C) Pharmacy Insurance Plan

☐ Priority ☐ Magellan ☐ Blue Cross Blue Shield of Michigan ☐ HAP ☒ University of Michigan Prescription Drug Plan

☐ Total Health Care ☐ Blue Care Network ☐ HealthPlus of Michigan ☐ Meridian Health Plan

D) Prescriber Information

Prescriber Name: _____ NPI: _____ Specialty: _____

DEA (required for controlled substance requests only): _____

Contact Name: _____ Contact Phone: _____ Contact Fax: _____

Health Plan Provider ID (if accessible): _____

E) Pharmacy Information (optional)

Pharmacy Name: _____ Pharmacy Telephone: _____

F) Requested Prescription Drug Information

Drug Name: _____ Strength: _____

Dosing Schedule: _____ Duration: _____

Diagnosis (specific) with ICD#: _____

Place of infusion/injection (if applicable): _____

Facility Provider ID/NPI: _____

Has the patient already started the medication? ☐ Yes ☐ No If so, when? _____

G) Rationale for Prior Authorization: (e.g., information such as history of present illness, past medical history, current medications, etc.; you may also attach chart notes to support your request if you believe they will assist with the review process).

H) Failed/Contraindicated Therapies

Drug Name	Strength	Dosing Schedule	Duration	Adverse Event/Specific Failure

I) Other Pertinent Information (Optional – to be filled out if other information is necessary such as relevant diagnostic labs, measures of response to treatment, etc.) Please refer to plan's website for additional information that may be necessary for review. Please note that sending this form with insufficient clinical information may result in extended review period or adverse determination.

I represent to the best of my knowledge and belief that the information provided is true, complete and fully disclosed. A person may be committing insurance fraud if false or deceptive information with the intent to defraud is provided.

Physician's Name: _____

Physician's Signature: _____

Date: _____

PA 218 of 1956 as amended requires the use of a standard prior authorization form by prescribers when a patient's health plan requires prior authorization for prescription drug benefits.

For Health Plan Use Only

Request Date: _____ **LOB:** _____

Approved: _____ **Denied:** _____

Approved By: _____ **Denied By:** _____

Effective Date: _____ **Reason for Denial:** _____

Additional Comments: _____

HUMAN RESOURCES BENEFITS OFFICE UNIVERSITY OF MICHIGAN | MagellanRx MANAGEMENT

Member's Last Name:

Member's First Name:

University of Michigan – Dupixent® (dupilumab)

Some of the information needed to make a determination for coverage is not specifically requested on the Michigan Prior Authorization Request Form for Prescription Drugs. To avoid delays in reviewing your request, please make sure to include all of the following information.

Initial Request – Atopic Dermatitis		
Does the member have a diagnosis of moderate to severe atopic dermatitis?	**Y**	**N**
Is the requested within the Food and Drug Administration (FDA) labeling for the submitted weight?	**Y**	**N**
Does the member have one of the following? ▪ A minimum body surface area (BSA) involvement of at least 10% ▪ An Eczema Area and Severity Index (EASI) score of at least 16 ▪ A Physician Global Assessment (PGA) score of at least 3 ***Please supply documentation of the member's current body surface area (BSA) coverage, Eczema Area and Severity Index (EASI) score, or Physician Global Assessment (PGA) score.***	**Y**	**N**
Does the member have more than 50% of their BSA impacted?	**Y**	**N**
Has the member had a previous trial of at least **ONE** therapy from at least **TWO** of the following preferred categories without adequate response? ▪ Topical calcineurin inhibitors (e.g., tacrolimus, pimecrolimus) ▪ Medium- or high-potency topical corticosteroids ▪ Topical phosphodiesterase (PDE) inhibitors (e.g., crisaborole)	**Y**	**N**
Please provide the member's treatment plan with all previous and concurrent therapies.		
The member will **NOT** be receiving concurrent treatment with another monoclonal antibody biologic, tumor necrosis factor (TNF) inhibitor, biologic response modifier, or potent non-biologic agent (e.g., abrocitinib, apremilast, tofacitinib, baricitinib, upadacitinib). Is this statement **TRUE**?	**Y**	**N**
Is the member 6 months of age or older? ***For pediatric members (under 18 years of age), please supply documentation of the member's current weight.***	**Y**	**N**
Is the medication being prescribed by or in consultation with a dermatologist or allergist?	**Y**	**N**

Continued on next page.

HUMAN RESOURCES BENEFITS OFFICE UNIVERSITY OF MICHIGAN | MagellanRx MANAGEMENT

Member's Last Name:

Member's First Name:

Initial Request – Eosinophilic Asthma		
Does the member have a diagnosis of moderate to severe asthma?	**Y**	**N**
Is the member currently utilizing a high-dose inhaled corticosteroid (ICS) product plus either a long-acting beta-2 agonist (LABA) or a long-acting muscarinic antagonist (LAMA)?	**Y**	**N**
Does the member have documentation of blood eosinophils greater than or equal to 150 cells/mcL, measured within the preceding six weeks? ***Please supply documentation of an eosinophil count (cells/mcL) with date.***	**Y**	**N**
Has the member been established on an alternative anti-IL-4/5 product (e.g., mepolizumab, reslizumab, benralizumab)?	**Y**	**N**
Please provide the member's treatment plan with all previous and concurrent therapies.		
The member will **NOT** be receiving concurrent treatment with another monoclonal antibody biologic, tumor necrosis factor (TNF) inhibitor, biologic response modifier, or potent non-biologic agent (e.g., abrocitinib, apremilast, tofacitinib, baricitinib, upadacitinib). Is this statement **TRUE**?	**Y**	**N**
Is the member 6 years of age or older?	**Y**	**N**
Is the medication being prescribed by an allergist; immunologist; pulmonologist; or an ear, nose, and throat (ENT) specialist?	**Y**	**N**

Continued on next page.

Member's Last Name:

Member's First Name:

Initial Request – Oral Corticosteroid (OCS) Dependent Asthma		
Does the member have a diagnosis of moderate to severe asthma?	**Y**	**N**
Is the member currently utilizing daily oral corticosteroid (OCS) and has the member been receiving OCS for at least 4 weeks in addition to a high-dose inhaled corticosteroid (ICS) product plus either a long-acting beta-2 agonist (LABA) or a long-acting muscarinic antagonist (LAMA)?	**Y**	**N**
Please provide the member's treatment plan with all previous and concurrent therapies.		
The member will **NOT** be receiving concurrent treatment with another monoclonal antibody biologic, tumor necrosis factor (TNF) inhibitor, biologic response modifier, or potent non-biologic agent (e.g., abrocitinib, apremilast, tofacitinib, baricitinib, upadacitinib). Is this statement **TRUE**?	**Y**	**N**
Is the member 6 years of age or older?	**Y**	**N**
Is the medication being prescribed by an allergist; immunologist; pulmonologist; or an ear, nose, and throat (ENT) specialist?	**Y**	**N**
Initial Request – Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)		
Does the member have a diagnosis of CRSwNP?	**Y**	**N**
Will the member use dupilumab in combination with intranasal corticosteroids unless unable to tolerate or contraindicated?	**Y**	**N**
Has the member tried and failed both of the following? ▪ Intranasal corticosteroids ▪ Surgical intervention	**Y**	**N**
Please provide the member's treatment plan with all previous and concurrent therapies.		
The member will **NOT** be receiving concurrent treatment with another monoclonal antibody biologic, tumor necrosis factor (TNF) inhibitor, biologic response modifier, or potent non-biologic agent (e.g., abrocitinib, apremilast, tofacitinib, baricitinib, upadacitinib). Is this statement **TRUE**?	**Y**	**N**
Is the member 18 years of age or older?	**Y**	**N**
Is the medication being prescribed by an allergist; immunologist; pulmonologist; or an ear, nose, and throat (ENT) specialist?	Y	N

Continued on next page.

Member's Last Name:

Member's First Name:

Initial Request – Eosinophilic Esophagitis (EoE)		
Does the member have a diagnosis of EoE?	**Y**	**N**
Does the member weigh at least 40 kg?	**Y**	**N**
Please provide chart notes or medical records demonstrating the member's diagnosis and current weight.		
Has the member tried and failed dietary avoidance or modifications?	**Y**	**N**
Has the member tried and failed or does the member have a contraindication to budesonide oral viscous suspension or fluticasone propionate aerosol inhalation?	**Y**	**N**
Please provide the member's treatment plan with all previous and concurrent therapies.		
The member will **NOT** be receiving concurrent treatment with another monoclonal antibody biologic, tumor necrosis factor (TNF) inhibitor, biologic response modifier, or potent non-biologic agent (e.g., abrocitinib, apremilast, tofacitinib, baricitinib, upadacitinib). Is this statement **TRUE**?	**Y**	**N**
Is the member 12 years of age or older?	**Y**	**N**
Is the medication being prescribed by or in consultation with an allergist; immunologist, pulmonologist; gastroenterologist; or an ear, nose, and throat (ENT) specialist?	**Y**	**N**
Initial Request – Prurigo Nodularis (PN):		
Does the member have a diagnosis of PN?	**Y**	**N**
Does the member have at least 20 nodular lesions?	**Y**	**N**
Has the member tried and failed or is the member contraindicated to at least one generic high-potency topical corticosteroid?	**Y**	**N**
Has the member had a trial and failure of **TWO** or more generic topical corticosteroid products or is the member contraindicated to **ALL** generic topical corticosteroid products? *(**Note:** High-potency topical corticosteroid from the previous question counts towards this requirement.)*	**Y**	**N**
Please provide the member's treatment plan with all previous and concurrent therapies.		

Continued on next page.

Member's Last Name:

Member's First Name:

Has the member tried and failed a non-steroid PN treatment (e.g., methotrexate, cyclosporine, phototherapy, topical pimecrolimus, topical tacrolimus)?	**Y**	**N**
Please provide chart notes or medical records demonstrating the member's diagnosis and number of nodular lesions.		
The member will **NOT** be receiving concurrent treatment with another monoclonal antibody biologic, tumor necrosis factor (TNF) inhibitor, biologic response modifier, or potent non-biologic agent (e.g., abrocitinib, apremilast, tofacitinib, baricitinib, upadacitinib). Is this statement **TRUE**?	**Y**	**N**
Is the member 18 years of age or older?	**Y**	**N**
Is the medication being prescribed by or in consultation with a dermatologist or allergist?	**Y**	**N**

Continued on next page.

HUMAN RESOURCES BENEFITS OFFICE UNIVERSITY OF MICHIGAN | Magellan Rx MANAGEMENT

Member's Last Name:

Member's First Name:

Renewal Request		
For all conditions: The member is **NOT** receiving concurrent treatment with another monoclonal antibody biologic, tumor necrosis factor (TNF) inhibitor, biologic response modifier, or potent non-biologic agent (e.g., abrocitinib, apremilast, tofacitinib, baricitinib, upadacitinib). Is this statement **TRUE**?	**Y**	**N**
For atopic dermatitis: Has the member had a positive clinical response to therapy, as documented by the member's specialist provider?	**Y**	**N**
For atopic dermatitis: Is the requested dose within FDA labeling for the member's submitted weight?	**Y**	**N**
For atopic dermatitis: Has the member experienced or maintained one of the following? ▪ A reduction in body surface area (BSA) involvement of a least 20% from baseline ▪ A decrease in Eczema Area and Severity Index (EASI) score of at least 50% from baseline ▪ A Physician Global Assessment (PGA) score of 0 or 1	**Y**	**N**
For eosinophilic asthma: Has the member experienced a decrease in the frequency of exacerbations and improvement in symptoms, as attested to by the member's specialist provider?	**Y**	**N**
For oral corticosteroid (OCS) dependent asthma: Has the member experienced one of the following? ▪ A decrease in their dose of oral corticosteroids by at least 50% ▪ A decrease in their dose of oral corticosteroids by **any** amount **AND** the member has experienced a decrease in the frequency of exacerbations and improvement in symptoms, as attested to by the member's specialist provider	**Y**	**N**
For CRSwNP, EoE, and PN: Does the member continue to have a beneficial response to therapy, as assessed by the member's specialist provider?	**Y**	**N**